Lugano response criteria are standardized rules used to describe how lymphoma responds to treatment. They translate imaging and clinical findings into shared categories like complete response or progression. They are commonly applied in Hodgkin lymphoma and many types of non-Hodgkin lymphoma. They are often used with PET/CT and CT scans in routine care and clinical trials.

Deauville score is a standardized way to interpret FDG PET imaging in oncology. It compares how much a suspected cancer area “lights up” versus normal reference tissues. It is most commonly used in lymphoma, especially Hodgkin lymphoma and some non-Hodgkin lymphomas. Clinicians use it to describe treatment response in a consistent, shared language.

iRECIST is a set of rules used to describe how a cancer changes on imaging during immunotherapy. It stands for “immunotherapy Response Evaluation Criteria in Solid Tumors.” It is most commonly used in clinical trials and research studies of immune checkpoint inhibitors. It helps clinicians report tumor response in a consistent, standardized way.

RECIST 1.1 is a standardized way to measure how solid tumors change in size on imaging over time. It helps clinicians describe whether cancer is shrinking, growing, or staying about the same during treatment. RECIST 1.1 is most commonly used in clinical trials and in some routine oncology imaging follow-up. It supports consistent communication between radiology, oncology, and research teams.

RECIST is a standardized way to describe how solid tumors change on imaging during and after cancer treatment. It helps clinicians and researchers use the same “rules” when they measure tumors on CT or MRI scans. RECIST is most commonly used in clinical trials and in oncology practices to assess treatment response. It turns scan measurements into clear response categories, such as shrinkage, stability, or growth.

RCB is short for **Residual Cancer Burden**. It is a **pathology-based way to measure how much cancer remains** after treatment given before surgery (neoadjuvant therapy). RCB is most commonly used in **breast cancer care** after neoadjuvant chemotherapy and/or targeted therapy. It helps clinicians describe treatment response in a more detailed way than “response” versus “no response.”

Residual cancer burden is a way to describe how much cancer remains after treatment given before surgery. It is most commonly used after neoadjuvant therapy, such as chemotherapy, targeted therapy, or endocrine therapy. It combines key pathology findings from the breast and lymph nodes into a standardized summary. In plain terms, it helps clinicians and patients understand “how much tumor is left” after treatment.

pCR most commonly means **pathologic complete response**. It describes **no remaining detectable cancer on pathology** in the treated area after therapy given before surgery. pCR is most often discussed after **neoadjuvant** (pre-surgery) chemotherapy, targeted therapy, immunotherapy, and/or radiation therapy. Clinicians use pCR to help describe treatment response and to support research and treatment planning.

Pathologic complete response is a pathology finding after cancer treatment. It means no remaining cancer is seen in the tissue removed and examined under a microscope. It is most commonly discussed after treatment given before surgery (neoadjuvant therapy). It is used in both routine cancer care and cancer clinical trials.

A Sentinel node is the first lymph node (or small group of nodes) that drains lymph fluid from a specific area of the body. It is commonly used in cancer care to check whether cancer cells have started to spread through the lymphatic system. Clinicians most often discuss the Sentinel node in cancers like breast cancer and melanoma. Testing the Sentinel node can help guide staging and treatment decisions.